Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282308 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT00282308 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 103 participants.
The verdict
NCT00282308, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
This was a Phase II, randomized, open-label, multicenter study designed to evaluate the immune response to vaccines after administration of 1000 mg of rituximab in subjects with active rheumatoid arthritis (RA) who were receiving background methotrexate (MTX).
Interventions
- DRUG Rituximab
- DRUG Methotrexate
- DRUG Methylprednisone
- BIOLOGICAL C. albicans
- BIOLOGICAL Tetanus toxoid adsorbed booster vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2006-01-23 |
| Est. Completion | 2012-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282308
The ClinicalTrials.gov registry entry for NCT00282308 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00282308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282308 about?
NCT00282308 is a clinical study titled "A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate". This was a Phase II, randomized, open-label, multicenter study designed to evaluate the immune response to vaccines after administration of 1000 mg of rituximab in subjects with active rheumatoid arthritis (RA) who were receiving background methotrexate (MTX).
What is the current status of trial NCT00282308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2006-01-23. Estimated completion is 2012-05-28.
What interventions are being tested in trial NCT00282308?
The interventions under investigation include: Rituximab (DRUG), Methotrexate (DRUG), Methylprednisone (DRUG), C. albicans (BIOLOGICAL), Tetanus toxoid adsorbed booster vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00282308?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.